Despite the fact that our data do not identify obesity as an independent risk factor for JIA, they suggest a negative influence on disease activity at baseline and an unfavorable impact on the therapeutic response to conventional DMADs and anti-TNF drugs. Here, TNF is linked to obesity due to melanocortin 4 receptor deficiency.